Full-Time

Senior Director

Resource Management, Global Clinical Operations

Posted on 5/16/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$214.5k - $284.5k/yr

+ Bonus + Incentive

Remote in USA

Remote

Category
Business & Strategy (1)
Required Skills
Forecasting
Data Analysis
Requirements
  • Advanced degree in Life Sciences, Business Administration, Operations Management, or a related field required.
  • Bachelor's degree with 12+ years of experience or MBA or Master's degree with 8+ years of experience strongly preferred.
  • Minimum 12+ years (with Bachelor's) or 8+ years (with MBA or Masters) of experience in clinical development, clinical operations, or business operations roles, with at least 5 years leading global resource or workforce management functions at a pharma or contract research organization.
  • Demonstrated experience implementing capacity planning, demand forecasting, and headcount management processes across a 1000+ person organization.
Responsibilities
  • Develop and implement global budget and resource planning/management strategy for GCO to ensure effective alignment of resources with business and portfolio priorities.
  • Build, maintain and optimize integrated Resource Budgeting, Resource Allocation and Resource Management models.
  • Partner with Finance, Office of GCO and GCO functional/regional leadership for the development of the Annual Operating Plan – including Opex & workforce resources.
  • Partner with Finance, Office of GCO and HR to integrate Opex & resource forecasts into annual and long-range planning cycles.
  • Establish and manage a centralized process and governance model for tracking, forecasting, and reporting Opex and workforce targets, allocation and utilization.
  • Partner with HR, Finance, Office of GCO & other functions for capacity planning and ensuring timely availability of resources to deliver on the portfolio.
  • Collaborate with functional/regional leadership to ensure consistent, data-driven workload forecasts and allocation across functions, geographies, and study portfolios.
  • Drive consistent adoption and optimization of resource management tools and processes to enable transparency and accuracy in planning.
  • Serve as a strategic advisor to the GCO leadership team on resource-related decisions, including prioritization, hiring, and FSP vendor utilization.
  • Lead cross-functional resource review forums to optimize resource planning and utilization, providing actionable analytics/insights and resolving conflicts or imbalances in resource allocation.
  • Partner with regions and functions to ensure alignment of strategic portfolio priorities and resourcing plans.
  • Lead development of dashboards and metrics for capacity utilization, resource allocation, and workforce utilization/optimization in partnership with Technology/ Digital groups.
  • Use predictive analytics to anticipate capacity challenges and inform scenario planning.
  • Generate analytics and insights relating to portfolio demand as well as resource availability/utilization and drive development of resource allocation plans that enhance efficiency and productivity.
  • Regularly monitor and assess resource utilization trends and identify areas of proactive adjustments/improvements to ensure optimal resource allocation.
  • Build and lead a small, high-performing global resource management network across Global Clinical Operations.
  • Promote a culture of accountability, data transparency, and continuous improvement.
  • Lead change management efforts to embed new tools, processes, and mindsets across a diverse and global organization.
  • Stay updated on industry trends, best practices and emerging technologies in resource management, applying relevant knowledge to improve organizational processes.
  • Matrix leadership responsibility for providing guidance, mentoring and coaching to regional/ functional resource planning team members on resource planning and management best practices.
Desired Qualifications
  • Expertise in resource management tools such as Anaplan, Planisware, Smartsheet or equivalent enterprise systems.
  • Experience with AI based resource management is a plus.
  • Oncology therapeutic area experience is a plus.
  • Global, matrixed leadership experience preferred.
  • Fluent in written and verbal English.
  • Exceptional communication and presentation skills for executive-level audiences.
  • Influential communicator able to negotiate resource trade-offs and align stakeholders at executive and operational levels.
  • Continuous improvement orientation with awareness of emerging best practices and technologies in resource management.
  • Demonstrated ability to lead through ambiguity and drive transformation.
  • Strong time management, organization, and stakeholder engagement skills.
  • Ability to partner effectively across all time zones and geographies.

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Brukinsa generated $1.1 billion in first-quarter 2026 sales, up 38%.
  • Sonrotoclax won FDA accelerated approval for relapsed or refractory mantle cell lymphoma.
  • TEVIMBRA plus ZIIHERA holds FDA Priority Review for HER2-positive gastric cancer.

What critics are saying

  • Revenue remains heavily dependent on Brukinsa, exposing BeOne to competitive erosion.
  • Sonrotoclax's approval depends on CELESTIAL-RRMCL confirmatory results.
  • TEVIMBRA diversification is unproven, with revenue still trailing Brukinsa materially.

What makes BeOne unique

  • BeOne combines Brukinsa, Tevimbra, and sonrotoclax across blood and solid tumors.
  • Its global trial network spans 30,000 patients and 75 approval markets.
  • Brukinsa remains the only BTK inhibitor with head-to-head PFS superiority.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at BeOne who can refer or advise you

Direct Contacts
Warm Intros
Hiring Managers
University Alumni

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-16%

1 year growth

-19%

2 year growth

-13%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...

INACTIVE